Individuals with Barrett’s esophagus are believed to be at 30–120× risk of developing esophageal adenocarcinoma (EAC). Early detection and endoscopic treatment of dysplasia/early cancer confers a significant advantage to patients under surveillance; however, most do not progress past the non-dysplastic state of Barrett’s esophagus (NDBE), which is potentially an inefficient distribution of health care resources.
This article aimed to review the outcomes of cost-effectiveness studies reducing low-value care in the context of endoscopic surveillance for non-dysplastic Barrett’s esophagus (NDBE).
A systematic search was conducted by two reviewers in accordance with PRISMA guidelines. Inclusion criteria: cost-utility analyses of endoscopic surveillance of NDBE patients with at least one treatment strategy focused on reduction of surveillance. A narrative synthesis of economic evaluations was undertaken, along with an in-depth analysis of input parameters contributing to stated Incremental cost-effectiveness ratios (ICER). Study appraisal was performed using the consolidated health economic evaluation reporting standards (CHEERS) tool.
10 Studies met inclusion criteria. There was significant variation in cost-model structures, input parameters, ICER values, and willingness-to-pay thresholds between studies. All studies except one concluded guideline-specified endoscopic surveillance for NDBE patients was not cost-effective. Studies that explored a modified surveillance by deselection of low-risk NDBE patients found it to be a cost-effective strategy.
Guideline specified endoscopic surveillance for NDBE was not found to be cost-effective in the studies examined. A modified endoscopic surveillance strategy removing individuals with the lowest risk for progression from NDBE to adenocarcinoma is likely to be cost-effective but is dependent on risk profile of patients excluded from surveillance.
This is a preview of subscription content,to check access.
Access this article
Similar content being viewed by others
Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TA, Tervonen H, Thursfield V, Ransom D, Shack L et al (2019) Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 20(11):1493–1505
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125):1023–1075
Patel N, Benipal B (2018) Incidence of esophageal cancer in the United States from 2001–2015: a United States cancer statistics analysis of 50 states. Cureus 10(12):e3709
Krishnamoorthi R, Borah B, Heien H, Das A, Chak A, Iyer PG (2016) Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett’s esophagus cohort. Gastrointest Endosc 84(1):40-46 e47
Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, de Koning HJ, Meester R, Inadomi JM, van Ballegooijen M (2015) An accurate cancer incidence in Barrett’s esophagus: a best estimate using published data and modeling. Gastroenterology 149(3):577-585 e574
Masclee GM, Coloma PM, de Wilde M, Kuipers EJ, Sturkenboom MC (2014) The incidence of Barrett’s oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off. Aliment Pharmacol Ther 39(11):1321–1330
Saxena N, Inadomi JM (2017) Effectiveness and cost-effectiveness of endoscopic screening and surveillance. Gastrointest Endosc Clin N Am 27(3):397–421
Runge TM, Abrams JA, Shaheen NJ (2015) Epidemiology of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 44(2):203–231
Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ (2010) Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 8(3):235–244
Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P (2011) Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365(15):1375–1383
Kerkhof M, van Dekken H, Steyerberg EW, Meijer GA, Mulder AH, de Bruine A, Driessen A, ten Kate FJ, Kusters JG, Kuipers EJ et al (2007) Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 50(7):920–927
Vennalaganti P, Kanakadandi V, Goldblum JR, Mathur SC, Patil DT, Offerhaus GJ, Meijer SL, Vieth M, Odze RD, Shreyas S et al (2017) Discordance among pathologists in the United States and Europe in diagnosis of low-grade dysplasia for patients with Barrett’s esophagus. Gastroenterology 152(3):564-570 e564
Coco DP, Goldblum JR, Hornick JL, Lauwers GY, Montgomery E, Srivastava A, Wang H, Odze RD (2011) Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus. Am J Surg Pathol 35(1):45–54
Moole H, Patel J, Ahmed Z, Duvvuri A, Vennelaganti S, Moole V, Dharmapuri S, Boddireddy R, Yedama P, Bondalapati N et al (2016) Progression from low-grade dysplasia to malignancy in patients with Barrett’s esophagus diagnosed by two or more pathologists. World J Gastroenterol 22(39):8831–8843
Hirst NG, Gordon LG, Whiteman DC, Watson DI, Barendregt JJ (2011) Is endoscopic surveillance for non-dysplastic Barrett’s esophagus cost-effective? Review of economic evaluations. J Gastroenterol Hepatol 26(2):247–254
Gordon LG, Mayne GC, Hirst NG, Bright T, Whiteman DC, Watson DI (2014) Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc 79(2):242-256.e246
Lindblad M, Bright T, Schloithe A, Mayne GC, Chen G, Bull J, Bampton PA, Fraser RJL, Gatenby PA, Gordon LG et al (2017) Toward more efficient surveillance of Barrett’s esophagus: identification and exclusion of patients at low risk of cancer. World J Surg 41(4):1023–1034
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E et al (2013) Consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health 16(2):231–250
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E et al (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health 16(2):e1-5
Shemilt I, Thomas J, Morciano M (2010) A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy 6(1):51–59
Young A, Rogers K, Davies L, Pilling M, Lovell K, Pilling S, Belk R, Shields G, Dodds C, Campbell M et al (2017) Evaluating the effectiveness and cost-effectiveness of British sign language improving access to psychological therapies: an exploratory study. Health Serv Deliv Res 5(24):1–196
Sculpher M, Manca A, Abbott J, Fountain J, Mason S, Garry R (2004) Cost effectiveness analysis of laparoscopic hysterectomy compared with standard hysterectomy: results from a randomised trial. BMJ 328(7432):134
Wojtyniak JG, Britz H, Selzer D, Schwab M, Lehr T (2020) Data digitizing: accurate and precise data extraction for quantitative systems pharmacology and physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 9(6):322–331
Zein H, Tran V, Abdelmotaleb G, Ahmed, Mohammed AT, Ahmed A, Iraqi A, Nguyen H (2015) How to Extract Data from Graphs using Plot Digitizer or Getdata Graph Digitizer. https://doi.org/10.13140/RG.2.2.17070.72002
Hao J, Critchley-Thorne R, Diehl DL, Snyder SR (2019) A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus. ClinicoEcon Outcomes Res 11:623–635
Provenzale D, Schmitt C, Wong JB (1999) Barrett’s esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 94(8):2043–2053
Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N (2003) Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 138(3):176–186
Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N (2006) Surveillance of Barrett’s oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 10(8):1–142
Gerson LB, Groeneveld PW, Triadafilopoulos G (2004) Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2(10):868–879
Omidvari AH, Ali A, Hazelton WD, Kroep S, Lee M, Naber SK, Lauren BN, Ostvar S, Richmond E, Kong CY et al (2020) Optimizing management of patients with Barrett’s esophagus and low-grade or no dysplasia based on comparative modeling. Clin Gastroenterol Hepatol 18(9):1961–1969
Peters Y, Honing J, Kievit W, Kestens C, Pestman W, Nagtegaal ID, van der Post RS, Siersema PD (2019) Incidence of progression of persistent nondysplastic Barrett’s esophagus to malignancy. Clin Gastroenterol Hepatol 17(5):869-877 e865
Singh S, Manickam P, Amin AV, Samala N, Schouten LJ, Iyer PG, Desai TK (2014) Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 79(6):897-909 e894
Kastelein F, van Olphen S, Steyerberg EW, Sikkema M, Spaander MCW, Looman CWN, Kuipers EJ, Siersema PD, Bruno MJ, de Bekker-Grob EW et al (2015) Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut 64(6):864–871
Gordon LG, Mayne GC, Hirst NG, Bright T, Whiteman DC, Watson DI, Australian Cancer Study Clinical Follow-Up S (2014) Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc 79(2):242-256 e246
Das A, Callenberg KM, Styn MA, Jackson SA (2016) Endoscopic ablation is a cost-effective cancer preventative therapy in patients with Barrett’s esophagus who have elevated genomic instability. Endosc Int Open 4(5):E549-559
Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ (2009) A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology 136(7):2101-2114 e2101
Gomersall JS, Jadotte YT, Xue Y, Lockwood S, Riddle D, Preda A (2015) Conducting systematic reviews of economic evaluations. Int J Evid Based Healthcare 13(3):170–178
Dr. Vissapragada is sponsored by a Ph.D. grant from The Hospital Research Foundation. Professor Watson received a Beat Cancer Hospital Research Package Grant which was funded by the Cancer Council of South Australia’s Beat Cancer Project on behalf of its donors and the State Government of South Australia Department of Health, together with the support of the Flinders Medical Centre Foundation, its donors and partners. This grant funded Dr. Norma Bulamu’s salary.
Drs. Vissapragada, Bulamu, Brumfitt, Yazbeck, Profs. Karnon and Watson have no conflicts of interest to or other financial ties to disclose.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
About this article
Cite this article
Vissapragada, R., Bulamu, N.B., Brumfitt, C. et al. Improving cost-effectiveness of endoscopic surveillance for Barrett’s esophagus by reducing low-value care: a review of economic evaluations. Surg Endosc 35, 5905–5917 (2021). https://doi.org/10.1007/s00464-021-08646-0